A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients

Annals of Nuclear Medicine

Volumn 17, Issue 4, 2003, Pages 297-303

  Fukumitsu, Nobuyoshi ^a   Uchiyama, Mayuki ^a   Mori, Yutaka ^a   Kishimoto, Kouichi ^a   Nakada, Jojiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

NTx; PICP; Prostate cancer; PSA; Skeletal metastasis

Indexed keywords

C TERMINAL PROPEPTIDE OF BLOOD TYPE I PROCOLLAGEN; COLLAGEN TYPE 1; OXIDRONATE TECHNETIUM TC 99M; PROCOLLAGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; URINE TYPE I COLLAGEN CROSSLINKED N TELOPEPTIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CORRELATION COEFFICIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0042013975     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988524     Document Type: Article

References (33)

1. Koizumi K, Uchiyama G, Komatsu H. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy-comparison with tumor markers and bone X-ray. Ann Nucl Med 1994; 8: 225-230.
2. Slack NH, Lane WW, Priore RL, Murphy GP. Prostate cancer. Urology 1986; 27: 205-213.
3. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-teropeptides in urine. J Bone Miner Res 1992; 7: 1251-1258.
4. Eyre DR. New biomarker of bone resorption. J Clin Endocrinol Metab 1992; 74: 470A-470C.
5. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-1332.
6. Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemil, Biomarkers and Prev 1993; 2: 125-129.
7. Rudnicki M, Jensen TL, Iversen P. Collagen derived serum markers in carcinoma of the prostate. Scand J Urol Nephrol 1995; 29: 317-321.
8. Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as markers of bone metastases in patients with prostate cancer. Eur Urol 1997; 31: 220-223.
9. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL. Collagen cross-linked metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994; 151: 909-913.
10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 1991; 324: 1156-1161.
11. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.
12. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376-381.
13. Wolff JM, Bares R, Jung PK, Buell U, Jakse G. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urologia Internationalis 1996; 56: 169-173.
14. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-1351.
15. Stokkel M, Zwinderman A, Zwartendijk J, Pauwels E, Eck-Smit B. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram. Eur J Nucl Med 1997; 24: 1215-1220.
16. Freitas JE, Gilvydas R, Ferry JD, Gonzalez JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991; 32: 1387-1390.
17. Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
18. Rudoni M, Antonini G, Farvo M, Baroli A, Brambilla M, Cardani G, et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-211.
19. Union Internationale Contre le Cancer: TNM classification of Malignant Tumors, 4th edn. International Union Against Cancer, Geneva, 1987.
20. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Statification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
21. Jacobs SC. Spread of prostatic cancer. Urology 1983; 21: 337-344.
22. Corrie D, Timmons JH, Bauman JM, Thompson IM. Efficacy of follow-up bone scans in carcinoma of the prostate. Cancer 1988; 61: 2453-2454.
23. Imai K, Tomaru Y, Ohnuki T, Yamanaka H, Sakai H, Kanetaka H, et al. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis. Cancer 1992; 69: 2983-2989.
24. Nguyen-Pamart M, Caty A, Feutrie ML, Fournier C, Gosselin P, Mazeman E. The diagnostic value of urinary crosslaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol 1992; 170: 299-303.
25. Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 1996; 156: 1691-1695.
26. Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate cancer. Eur Urol 1997; 31: 220-223.
27. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 1061-1064.
28. Fukumitsu N, Uchiyama M, Mori Y, Yanada S, Hatano T, Igarashi H, et al. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 2002; 51: 814-818.
29. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27: 187-192.
30. di Sant'Agnese PA, Cockett TK. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994; 152: 1927-1931.
31. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett TK, Abrahamsson P-A. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996; 48: 58-62.
32. Akimoto S, Furuya Y, Akakura K, Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J 1998; 45: 97-104.
33. Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263: 507-508.